2-[4-(N-monomethylamino)phenyl]-6-hydroxybenzothiophene | 1248623-45-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 2-[4-(N-monomethylamino)phenyl]-6-hydroxybenzothiophene
• 英文别名: 2-[4-(methylamino)phenyl]-1-benzothiophen-6-ol
• CAS: 1248623-45-1
• 化学式: C₁₅H₁₃NOS
• 分子量: 255.34
• InChiKey: HINKGUIPFOLHHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  60.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[4-(N-monomethylamino)phenyl]-6-hydroxybenzothiophene 、 （2-溴乙氧基）-特丁基二甲基硅烷 在 potassium carbonate 作用下， 以 异丁酰胺 为溶剂， 反应 24.0h， 以43%的产率得到2-[4-(N-monomethylamino)phenyl]-6-[2-(t-butyldimethylsilyloxy)ethoxy]benzothiophene
  参考文献：
  名称：

  2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT

  摘要：

  2-芳基苯并噻吩衍生物或其药用可接受盐，其制备方法，以及包含其作为活性成分的用于诊断或治疗退行性脑疾病的药物组合物。由于式1中的2-芳基苯并噻吩衍生物具有相对较高的β-淀粉样蛋白结合亲和力，因此当它们与放射性同位素标记时，它们可以作为诊断试剂用于通过非侵入性技术早期诊断阿尔茨海默病： 其中R1-R4，V，W，X，Y和Z如规范的详细描述中所定义。此外，当含有2-芳基苯并噻吩衍生物的药物组合物与低分子量β-淀粉样蛋白结合化合物结合时，最小化了恶性高分子量β-淀粉样蛋白沉积物的生成。因此，该药物组合物可用作治疗阿尔茨海默病等退行性脑疾病的治疗剂。

  公开号：

  US20100261727A1

文献信息

• Novel Imaging Agents for Detecting Neurological Dysfunction
  申请人：Kolb Hartmuth C.

  公开号：US20110046378A1

  公开（公告）日：2011-02-24

  Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease

  本文披露了一种诊断哺乳动物阿尔茨海默病或其易感性的化合物和方法，该方法包括向哺乳动物施用诊断有效量的放射性标记化合物，所述化合物选自放射性标记的黄酮类、香豆素类、咔唑类、喹啉酮类、香豆素酮类、咪唑类和三唑类衍生物组，使化合物分布到脑组织中，并成像脑组织，其中与正常结合水平相比，化合物与脑组织的结合增加表明该哺乳动物正在患有或有发展阿尔茨海默病的风险。
• 2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient
  申请人：Chi Dae Yoon

  公开号：US08497260B2

  公开（公告）日：2013-07-30

  2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R1-R4, V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.

  本发明涉及2-芳基苯并噻吩衍生物或其药学上可接受的盐，其制备方法以及含有其作为活性成分的用于诊断或治疗退行性脑病的制药组合物。由于式1中的2-芳基苯并噻吩衍生物具有相对较高的β-淀粉样蛋白结合亲和力，因此当它们被标记为放射性同位素时，它们可以用于非侵入性技术诊断早期阿尔茨海默病的诊断试剂。其中，R1-R4、V、W、X、Y和Z如规范的详细描述中所定义。此外，当含有2-芳基苯并噻吩衍生物的制药组合物与低分子量β-淀粉样肽结合化合物结合时，可以最小化致恶性高分子量β-淀粉样沉积物的产生。因此，该制药组合物可用作治疗退行性脑病，如阿尔茨海默病的治疗剂。
• US8497260B2
  申请人：——

  公开号：US8497260B2

  公开（公告）日：2013-07-30
• 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：Chi Dae Yoon

  公开号：US20100261727A1

  公开（公告）日：2010-10-14

  2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R 1 -R 4 , V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.

  2-芳基苯并噻吩衍生物或其药用可接受盐，其制备方法，以及包含其作为活性成分的用于诊断或治疗退行性脑疾病的药物组合物。由于式1中的2-芳基苯并噻吩衍生物具有相对较高的β-淀粉样蛋白结合亲和力，因此当它们与放射性同位素标记时，它们可以作为诊断试剂用于通过非侵入性技术早期诊断阿尔茨海默病： 其中R1-R4，V，W，X，Y和Z如规范的详细描述中所定义。此外，当含有2-芳基苯并噻吩衍生物的药物组合物与低分子量β-淀粉样蛋白结合化合物结合时，最小化了恶性高分子量β-淀粉样蛋白沉积物的生成。因此，该药物组合物可用作治疗阿尔茨海默病等退行性脑疾病的治疗剂。